INTRODUCTION

C hloramphenicol is 2,2-dichloro-N-[(1R, 2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-acetamide
, it was originally isolated as a substance produced by certain strains of the soil organism Streptomyces venezuelae, but is now produced synthetically. [1] Chloramphenicol usually acts as a bacteriostatic antibiotic with a broad spectrum of action against both Gram-positive and Gram-negative bacteria, as well as some other organisms, but at higher concentrations or against some very susceptible organisms it can be bactericidal. [1] It is used in the treatment of human infection with Salmonella typhi (typhoid) and other forms of salmonellosis, and other lifethreatening infections of the central nervous system and respiratory tract. [2] In veterinary medicine, chloramphenicol is used for the treatment of a variety of infections in animals, particularly those caused by anaerobic bacteria or those that are resistant to other antimicrobial agents. Chloramphenicol in animals is well absorbed by both oral and parenteral routes. [3] Th e risk of life threatening adverse eff ects (particularly bone marrow aplasia) and resistance, has severely limited the clinical usefulness of chloramphenicol, although it is still widely used in some countries (including Nigeria). [1] Metal complexes with active pharmaceuticals in which the drug molecules play the role of a ligand have been reported. [4] [5] [6] [7] Chloramphenicol -metal complexes with Zn, Cd, Sn and Pb have been synthesized, with the spectral data of the complexes indicating deprotonation and coordination of the secondary alcoholic OH group with metal ions, but the amide group does not participate in coordination. [8] Th e nitro group has also been demonstrated to be involved in coordination in a chloramphenicol -Ni.
As a result of such interactions, metal ions have been reported to signifi cantly alter the absorption and consequently the bioavailability of diff erent drugs especially antibiotics. [10] [11] [12] Th is study was therefore aimed at determining the in vitro availability of chloramphenicol in simulated gastric and intestinal media in the presence of Cd and Pb, two metals that are commonly found as contaminants in drinking water, food, drugs and environmental samples.
MATERIAL AND METHODS
Equipment and reagents
Chloramphenicol reference standard was obtained as a gift from Doyin Pharmaceuticals Nigeria Ltd. Chloramphenicol capsules were products of Green Field Pharmaceutical (JIANGSU) Co. Ltd., China (Batch-04-5485). Th e metal nitrates and other chemical reagents used were of analytical grade. Dissolution studies were performed using a ERWEKA (GMBH) dissolution apparatus. A double scanning UV/VIS spectrophotometer (Helios Zeta, Model 164617) was used to monitor the drug content.
Identification and assay of chloramphenicol
Both the chloramphenicol reference standard and chloramphenicol capsules were identifi ed and assayed using offi cial methods. [13] Preparation of dissolution media Dissolution was carried out in simulated gastric juice (containing 0.1M hydrochloric acid) and intestinal pH (phosphate buff er pH 9). Both media were prepared using offi cial methods. [13] Preparation of calibration curve Stock solutions (1 mg/ml) of chloramphenicol reference standard were prepared in 0.1M hydrochloric acid and phosphate buff er pH 9.
Th e absorbance of a 50 μg/ml solution was measured in the range of 200 -350 nm, which showed maxima at 278 nm. Successive serial dilutions of the stock were done to obtain standard solutions of concentration 10, 20, 30, 40 and 50 μg/ml. Th e absorbance of each solution was measured at the maxima (278 nm). [13] A plot of concentration against the corresponding absorbance was done in the case of each media. A straight line was obtained which obeyed the Beer-Lambert's law in each case. Th e chloramphenicol content in the two media during the in vitro availability studies were extrapolated from the calibration curves.
Availability of chloramphenicol
Th e in vitro availability of chloramphenicol in simulated gastric juice and intestinal pH at 37 o C was determined using dissolution apparatus as outlined in BP (2002) [13] with slight modifi cation to the top of the basket in order to prevent air entrapment during dissolution. [14] A capsule of chloramphenicol (250 mg) was placed in the dissolution basket and allowed into the dissolution medium. Th e dissolution process was monitored over a period of 180 minutes, with aliquots (10 ml) being withdrawn at 15 minutes intervals and assayed for drug content available. Th e volume of the dissolution medium was maintained after each withdrawal by an immediate replacement with 10 ml of the dissolution medium maintained at the same temperature in the same bath.
For the in vitro availability of chloramphenicol in the presence of Cd and Pb, the drug and the nitrate salts of each of the metals were reacted in a ratio of 2:1 (i.e 250 mg chloramphenicol:125 mg of metal) respectively in each of the dissolution media (1L). Th e process described above was then repeated to determine the drug content after each sampling.
Statistical Analysis
Th e results obtained were statistically analyzed using student t-test with GraphPad Prism 4 software. P values less than 0.05 were considered to be statistically signifi cant.
RESULTS AND DISCUSSION
Th e results of the identifi cation test for both chloramphenicol reference standard and capsules revealed the presence of the active ingredient, and the content assayed was within the offi cial limits (98 -105%). [13] For the quantitative determination of drug content, it was observed that the calibration curves of chloramphenicol in both simulated gastric juice (0.1M hydrochloric acid) and intestinal pH (phosphate buff er pH 9) at 278 nm obeyed the Beer-Lambert's law. Th e linear relationship between absorbance (A) and concentration (C in % w/v) is given by the regression equations A = 0.030C + 0.003 and A = 0.033C + 0.002 for chloramphenicol in 0.1M hydrochloric acid and phosphate buff er pH 9 respectively. Th e coeffi cient of correlation (r) in each case is 0.999. Th e calculated molar absorptivities were 1,061 ± 0.0004 M -1 cm Tables 1 and 2 as well as in Figures  2 and 3 . Th e intrinsic fi rst order dissolution rate constants and dissolution times T 50% and T 90% of chloramphenicol alone and in the presence of Pb and Cd are shown in Table 3 .
In simulated gastric juice at 37 o C, chloramphenicol achieved an availability of 89% after 180 minutes, with T 50% and T 90% values of 28.7 and 182 minutes respectively. In the presence of Pb and Cd, c hloramphenicol achieved an availability of 88.6 and 86% after 180 minutes. Th e overall availability of chloramphenicol in simulated gastric juice at 37 o C was not signifi cantly aff ected (P<0.05) by the presence of the metals, although the drug content available after each sampling was aff ected. Th e consistent decline in the content of chloramphenicol available in the presence of Pb throughout the study did not however signifi cantly change (P<0.05) the T 50% (29.5 minutes) and T 90% (182.8 minutes) values. Cd appears to increase the availability of chloramphenicol for the fi rst 45 minutes resulting in signifi cant reduction (P<0.05) of the T 50% (12.6 minutes). Th ereafter a decline in drug content was observed to the end of the study resulting in an increased T 90% (188.4 minutes) value. A similar trend was observed in in vitro availability and interaction studies of ciprofl oxacin and ofl oxacin in the presence of some metals. [11, 15] Th e insignifi cant reduction in drug content observed in the presence of Pb and Cd in the simulated gastric juice may be because the complexation of certain drugs by polyvalent cations is not favored in acid medium. [15] In the simulated intestinal pH, chloramphenicol achieved an availability of 82.5% after 180 minutes, with T 50% and T 90% values of 31.0 and 196.4 minutes respectively. In presence of Pb and Cd, the content of chloramphenicol available was drastically reduced to 63.2% in both cases. Th e overall availability of chloramphenicol in simulated intestinal pH at 37 o C was signifi cantly reduced in the presence of Pb (P<0.01), as well as in the presence of Cd (P<0.001). Th e consistency and degree of decline in the content of chloramphenicol available with time in the presence of both Pb and Cd was underscored by the signifi cant change (P<0.01) in both the T 50% and T 90% values. Th e T 50% values where increased from 31.0 minutes to 91.8 and 124.3 minutes for chloramphenicol in the presence of Pb and Cd respectively. Th ere was also a signifi cant increase (P<0.01) in the T 90% values from 196.4 minutes to 256.3 minutes in both cases. Another reason could be the complexation of the drug by the metal resulting in reduced availability due to an increase in T 50% and T 90% values. A similar trend was also reported where the availability of ofl oxacin was markedly reduced in the presence of diff erent metals (including Cd) in a medium of pH 9 at 37 o C. [11] 
CONCLUSION
In this study, the in vitro availability of chloramphenicol was reduced in the presence of Pb and Cd. Th is eff ect was more signifi cant in simulated intestinal pH than in simulated gastric juice in terms of magnitude and linearity. Furthermore, the pH of the medium is an important factor in the dissolution and consequent availability of the drug. Th us, the concurrent use of chloramphenicol with water, food and drugs containing Pb and Cd metal ions may result in decreased absorption, decreased serum concentration and decreased bioavailability of chloramphenicol, leading to therapeutic failure. Further studies on the eff ect of actual concentrations of these metals found as contaminants in water, food and drugs on the bioavailability of chloramphenicol should be evaluated.
